BIOMÉRIEUX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100 EUR | -2.25% |
|
-0.70% | -0.60% |
| Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
| Apr. 26 | BIOMÉRIEUX : Berenberg raises its target | CF |
| Sales 2024 * | 3.9B 4.16B | Sales 2025 * | 4.19B 4.47B | Capitalization | 11.82B 12.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 470M 501M | Net income 2025 * | 528M 563M | EV / Sales 2024 * | 2.95 x |
| Net cash position 2024 * | 308M 328M | Net cash position 2025 * | 487M 519M | EV / Sales 2025 * | 2.7 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
22.9
x | Employees | 13,696 |
| Yield 2024 * |
0.87% | Yield 2025 * |
1% | Free-Float | 36.2% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More press releases
More news
| 1 day | -2.25% | ||
| 1 week | -0.70% | ||
| Current month | -2.20% | ||
| 1 month | -2.20% | ||
| 3 months | -1.38% | ||
| 6 months | +12.97% | ||
| Current year | -0.60% |
1 week
98.65
102.60
1 month
94.60108.90
Current year
94.26108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 16 M€ | -5.68% | ||
| 0.26% | 1,120 M€ | -0.11% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 100 | -2.25% | 147,236 |
| 24-04-29 | 102.3 | +0.79% | 86,178 |
| 24-04-26 | 101.5 | +2.01% | 93,439 |
| 24-04-25 | 99.5 | -1.19% | 60,768 |
| 24-04-24 | 100.7 | -0.69% | 97,428 |
Real-time Euronext Paris, April 30, 2024 at 11:38 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
100
EUR
Average target price
112.8
EUR
Spread / Average Target
+12.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.60% | 12.63B | |
| -9.59% | 7.67B | |
| +1.82% | 5.42B | |
| +0.02% | 4.57B | |
| +7.32% | 4.56B | |
| -47.68% | 3.51B | |
| +6.42% | 2.59B | |
| -14.59% | 2.05B | |
| +2.25% | 1.77B | |
| -8.29% | 1.79B |
- Stock Market
- Equities
- BIM Stock
